Sponsors (4)
The bill speeds temporary importation to reduce drug shortage-related disruptions and increases transparency, but it raises patient safety risks, may weaken domestic supply incentives, and could impose additional costs on taxpayers.
Patients with chronic conditions can get access to therapeutically equivalent imported drugs faster via a 60-day expedited authorization when domestic shortages occur, reducing interruptions in critical medication access.
Hospitals and health systems can avoid care disruptions because marginal markets can be designated as shortages, enabling expedited reviews and inspections to restore supply more quickly.
Taxpayers and the public gain increased transparency through a required annual report on the number of drugs authorized for temporary importation.
Patients with chronic conditions face higher safety risk if imported drugs prove less safe due to differing foreign approvals or limited inspections, potentially causing adverse events.
Hospitals, health systems, and patients may experience weaker long-term domestic supply resilience because temporary importation and expedited pathways could reduce manufacturers' incentives to invest in preventing future shortages.
Taxpayers could indirectly bear additional costs if expedited reviews or inspections require more FDA resources and the bill does not provide offsetting funding.
Based on analysis of 2 sections of legislative text.
Allows FDA to temporarily authorize importation of certain foreign-approved drugs during shortages or in narrowly defined low-competition markets and requires annual reporting of authorizations.
Creates a temporary FDA importation pathway to allow certain foreign-approved versions of drugs to be imported when the U.S. faces a shortage or when a drug market is judged "marginally competitive." It defines criteria for treating a market as marginally competitive, sets procedural timelines (authorization within 60 days, up to 3 years), lists grounds for denial, and requires annual reporting on how many drugs were authorized under the new authority.
Official title: Allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages.
Introduced July 17, 2025 by Amy Klobuchar · Last progress July 17, 2025